2 news items
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
RNAZ
29 May 24
with geopolitical events and pandemics, including the COVID-19 coronavirus. For a discussion of these and other risks and uncertainties, and other important
TransCode Therapeutics Reports 2023 Results; Provides Business Update
RNAZ
3 Apr 24
with TransCode's dependence on third parties; and risks associated with geopolitical events and pandemics, including the COVID-19 coronavirus
- Prev
- 1
- Next